FT商學院

Schizophrenia: the new drug set to tackle the ‘cancer of psychiatry’

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness

When a rash broke out on the hand of a patient taking part in the trial of a promising schizophrenia drug, clinical investigator Greg Mattingly began to fret that it might be an allergic reaction.

Instead, it turned out to be a mark of success: the patient, in his fifties, had landed his first job in more than a decade as a waiter, and the skin inflammation was a side effect not of the drug, but of washing dishes.

Securing a full-time job may seem unremarkable, but for most people living with schizophrenia, it can represent a triumph against the odds.

您已閱讀4%(558字),剩餘96%(14593字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×